Fulgent Genetics (FLGT) Total Non-Current Liabilities (2016 - 2026)

Fulgent Genetics has disclosed Total Non-Current Liabilities across 11 years of filings, most recently posting $102.8 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $102.8 million, up 33.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $102.8 million (up 33.82% YoY), and the FY2025 annual result was $99.2 million, up 9.66% from the prior year.
• Total Non-Current Liabilities came in at $102.8 million for Q1 2026 at Fulgent Genetics, up from $99.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $149.2 million in Q2 2022 to a low of $74.7 million in Q2 2023.
• The 5-year median for Total Non-Current Liabilities is $97.3 million (2024), against an average of $98.9 million.
• Across the five-year window, Total Non-Current Liabilities plunged 49.96% in 2023 and soared 33.82% in 2026, its largest moves.
• Fulgent Genetics' Total Non-Current Liabilities stood at $97.9 million in 2022, then slipped by 1.92% to $96.1 million in 2023, then retreated by 5.85% to $90.4 million in 2024, then gained by 9.66% to $99.2 million in 2025, then increased by 3.69% to $102.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $102.8 million (Q1 2026), $99.2 million (Q4 2025), and $91.8 million (Q3 2025), per Business Quant data.